Is AVXL or JANX more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Janux Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -11.43% -10.72% Janux Therapeutics N/A -11.89% -11.13%

Does the media refer more to AVXL or JANX?

In the previous week, Anavex Life Sciences had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Anavex Life Sciences and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.36 beat Anavex Life Sciences' score of 0.48 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SVRA or AVXL?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.15 N/A

Is SVRA or AVXL more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Anavex Life Sciences N/A -11.43% -10.72%

Does the media favor SVRA or AVXL?

In the previous week, Anavex Life Sciences had 3 more articles in the media than Savara. MarketBeat recorded 5 mentions for Anavex Life Sciences and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Anavex Life Sciences' score of 0.48 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVXL or AVTX more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -11.43% -10.72% Avalo Therapeutics N/A -58.03% -48.22%

Does the media refer more to AVXL or AVTX?

In the previous week, Avalo Therapeutics had 5 more articles in the media than Anavex Life Sciences. MarketBeat recorded 10 mentions for Avalo Therapeutics and 5 mentions for Anavex Life Sciences. Avalo Therapeutics' average media sentiment score of 0.83 beat Anavex Life Sciences' score of 0.48 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, AVXL or SLDB?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.15 N/A Solid Biosciences N/A N/A -$174.32M -$1.91 N/A

Is AVXL or SLDB more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -11.43% -10.72% Solid Biosciences N/A -71.35% -60.58%

Does the media refer more to AVXL or SLDB?

In the previous week, Anavex Life Sciences had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Anavex Life Sciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Anavex Life Sciences' score of 0.48 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AVXL or CVAC?

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 714.25%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Anavex Life Sciences (AVXL) Competitors

$2.62 -0.04 (-1.50%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.62 +0.00 (+0.19%)

As of 09/11/2026 07:30 PM Eastern

Compare

AVXL vs. JANX, SVRA, AVTX, SLDB, and CVAC

Should you buy Anavex Life Sciences stock or one of its competitors? Anavex Life Sciences's main competitors and comparable companies include Janux Therapeutics (JANX), Savara (SVRA), Avalo Therapeutics (AVTX), Solid Biosciences (SLDB), and CureVac (CVAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anavex Life Sciences compare to Janux Therapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Anavex Life Sciences' return on equity of -11.43% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.43%	-10.72%
Janux Therapeutics	N/A	-11.89%	-11.13%

Anavex Life Sciences has higher earnings, but lower revenue than Janux Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
Janux Therapeutics	$10M	104.55	-$113.62M	-$1.64	N/A

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Anavex Life Sciences presently has a consensus target price of $21.33, indicating a potential upside of 714.25%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 113.23%. Given Anavex Life Sciences' higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Anavex Life Sciences had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Anavex Life Sciences and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.36 beat Anavex Life Sciences' score of 0.48 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market.

Summary

Janux Therapeutics beats Anavex Life Sciences on 8 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Savara?

Savara (NASDAQ:SVRA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Savara currently has a consensus price target of $10.00, indicating a potential upside of 88.68%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 714.25%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Anavex Life Sciences had 3 more articles in the media than Savara. MarketBeat recorded 5 mentions for Anavex Life Sciences and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Anavex Life Sciences' score of 0.48 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.9% of Savara shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A

Savara has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Anavex Life Sciences' return on equity of -11.43% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Anavex Life Sciences	N/A	-11.43%	-10.72%

Summary

Anavex Life Sciences beats Savara on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Avalo Therapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Avalo Therapeutics had 5 more articles in the media than Anavex Life Sciences. MarketBeat recorded 10 mentions for Avalo Therapeutics and 5 mentions for Anavex Life Sciences. Avalo Therapeutics' average media sentiment score of 0.83 beat Anavex Life Sciences' score of 0.48 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences has higher earnings, but lower revenue than Avalo Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
Avalo Therapeutics	$60K	14,408.59	-$78.26M	-$4.37	N/A

Anavex Life Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anavex Life Sciences' return on equity of -11.43% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.43%	-10.72%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Anavex Life Sciences currently has a consensus price target of $21.33, suggesting a potential upside of 714.25%. Avalo Therapeutics has a consensus price target of $45.10, suggesting a potential upside of 179.78%. Given Anavex Life Sciences' higher probable upside, research analysts clearly believe Anavex Life Sciences is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Anavex Life Sciences and Avalo Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Solid Biosciences?

Anavex Life Sciences (NASDAQ:AVXL) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Anavex Life Sciences currently has a consensus target price of $21.33, indicating a potential upside of 714.25%. Solid Biosciences has a consensus target price of $18.18, indicating a potential upside of 108.99%. Given Anavex Life Sciences' higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Anavex Life Sciences' return on equity of -11.43% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.43%	-10.72%
Solid Biosciences	N/A	-71.35%	-60.58%

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Anavex Life Sciences had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Anavex Life Sciences and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Anavex Life Sciences' score of 0.48 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Anavex Life Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

Summary

Anavex Life Sciences beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to CureVac?

Anavex Life Sciences (NASDAQ:AVXL) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

CureVac has a net margin of 199.92% compared to Anavex Life Sciences' net margin of 0.00%. Anavex Life Sciences' return on equity of -11.43% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.43%	-10.72%
CureVac	199.92%	-23.03%	-19.09%

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Anavex Life Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

In the previous week, Anavex Life Sciences had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Anavex Life Sciences and 0 mentions for CureVac. Anavex Life Sciences' average media sentiment score of 0.48 beat CureVac's score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anavex Life Sciences	Neutral
CureVac	Neutral

CureVac has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 714.25%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Anavex Life Sciences beats CureVac on 9 of the 15 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$242.87M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.72%
P/E Ratio	-17.47	14.18	274.94	25.36
Price / Sales	N/A	1,374.96	685.43	116.38
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	2.38	15.12	10.33	6.20
Net Income	-$46.38M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-8.39%	-4.34%	-3.32%	-2.35%
1 Month Performance	-19.88%	0.54%	-0.53%	-3.23%
1 Year Performance	-72.04%	40.74%	23.51%	8.79%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	1.6741 of 5 stars	$2.62 -1.5%	$21.33 +714.2%	-72.0%	$242.87M	N/A	N/A	40	News Coverage Analyst Forecast
JANX Janux Therapeutics	3.5932 of 5 stars	$18.22 +1.1%	$36.46 +100.1%	-28.9%	$1.10B	$10M	N/A	30	Positive News Gap Down
SVRA Savara	2.1532 of 5 stars	$5.39 +2.5%	$10.14 +88.2%	+48.9%	$1.08B	N/A	N/A	20	Positive News
AVTX Avalo Therapeutics	3.4542 of 5 stars	$19.34 -1.3%	$45.10 +133.2%	+51.4%	$1.05B	$60K	N/A	40	News Coverage Analyst Downgrade Insider Trade
SLDB Solid Biosciences	2.0335 of 5 stars	$9.58 -1.9%	$18.18 +89.8%	+61.4%	$1.05B	N/A	N/A	100	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. JANX, SVRA, AVTX, SLDB, and CVAC

How does Anavex Life Sciences compare to Janux Therapeutics?

Summary

How does Anavex Life Sciences compare to Savara?

Summary

How does Anavex Life Sciences compare to Avalo Therapeutics?

Summary

How does Anavex Life Sciences compare to Solid Biosciences?

Summary

How does Anavex Life Sciences compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. JANX, SVRA, AVTX, SLDB, and CVAC

How does Anavex Life Sciences compare to Janux Therapeutics?

Is AVXL or JANX more profitable?

Which has higher earnings and valuation, AVXL or JANX?

Do institutionals and insiders believe in AVXL or JANX?

Do analysts prefer AVXL or JANX?

Does the media refer more to AVXL or JANX?

Which has more volatility and risk, AVXL or JANX?

Summary

How does Anavex Life Sciences compare to Savara?

Do analysts rate SVRA or AVXL?

Does the media favor SVRA or AVXL?

Do insiders & institutionals believe in SVRA or AVXL?

Which has higher earnings and valuation, SVRA or AVXL?

Which has more volatility & risk, SVRA or AVXL?

Is SVRA or AVXL more profitable?

Summary

How does Anavex Life Sciences compare to Avalo Therapeutics?

Does the media refer more to AVXL or AVTX?

Which has better earnings & valuation, AVXL or AVTX?

Which has more volatility & risk, AVXL or AVTX?

Do insiders and institutionals hold more shares of AVXL or AVTX?

Is AVXL or AVTX more profitable?

Do analysts prefer AVXL or AVTX?

Summary

How does Anavex Life Sciences compare to Solid Biosciences?

Do analysts prefer AVXL or SLDB?

Is AVXL or SLDB more profitable?

Do institutionals and insiders have more ownership in AVXL or SLDB?

Does the media refer more to AVXL or SLDB?

Which has preferable earnings & valuation, AVXL or SLDB?

Which has more volatility and risk, AVXL or SLDB?

Summary

How does Anavex Life Sciences compare to CureVac?

Is AVXL or CVAC more profitable?

Do institutionals & insiders hold more shares of AVXL or CVAC?

Which has more volatility and risk, AVXL or CVAC?

Does the media refer more to AVXL or CVAC?

Which has preferable valuation & earnings, AVXL or CVAC?

Do analysts recommend AVXL or CVAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools